Cumberland Pharmaceuticals Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- A. J. Kazimi
- Full Time Employees
- 88
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2525 West End Avenue Nashville TN United States of America 37203
- IPO Date
- Aug 11, 2009
- CIK
- 0001087294
- Website
- cumberlandpharma.com
- Similar Companies
- Business
- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription products for hospital acute care, gastroenterology, oncology, and infectious diseases. Founded in 1999 and headquartered in Nashville, Tennessee, the company markets its portfolio primarily in the United States through dedicated hospital, field, and oncology sales divisions while establishing international partnerships for registration and distribution in markets including China, Saudi Arabia, Mexico, and Australia. Its core products include Acetadote (acetylcysteine injection) for acetaminophen poisoning; Caldolor (ibuprofen injection) for pain and fever, including in pediatric patients as young as three months and pre-operative use; Kristalose (lactulose oral solution), a prescription laxative for constipation; Sancuso (granisetron transdermal patch) for prevention of chemotherapy-induced nausea and vomiting; Vaprisol (conivaptan injection) for euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin injection) for serious bacterial infections such as hospital-acquired pneumonia and complicated skin infections. Recent developments include the October 2025 formation of Talicia Holdings Inc., a joint venture with RedHill Biopharma Ltd., where Cumberland invested $4 million for a 30% stake and assumed U.S. distribution responsibilities for Talicia (omeprazole, amoxicillin, rifabutin capsules), the FDA-approved all-in-one therapy for Helicobacter pylori infection; this arrangement enables Cumberland to record Talicia sales and share net revenues equally while leveraging its sales force for promotion. In the same month, Vibativ was added to a national group purchasing agreement with Premier Inc., enhancing access for over 4,350 U.S. hospitals and providers. Earlier in 2025, Cumberland reported positive Phase 2 FIGHT DMD trial results demonstrating improved heart function with ifetroban in Duchenne muscular dystrophy patients, alongside NMPA approval of Vibativ in China via partner SciClone Pharmaceuticals, regulatory approval of Caldolor in Mexico through PiSa Pharmaceuticals, and Vibativ launch in Saudi Arabia by Tabuk Pharmaceuticals; the company also posted 11.6% fourth-quarter 2024 revenue growth to $10.4 million.
Company News
Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
Possible Generic Drug Tariffs and 2 Microcaps
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma Announces Up To $19.4 Million Private Placement
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
Cumberland's Ifetroban Shows Potential to Limit Metastasis